Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
Jesús García-Donás(Universidad San Pablo CEU), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), José Ángel Arranz(Hospital General Universitario Gregorio Marañón), Begoña Mellado(Hospital Clínic de Barcelona), José A. Martinez‐Climent(Marqués de Valdecilla University Hospital), Daniel Castellano(Universidad Complutense de Madrid), Aranzazu González del Alba(Hospital Universitario Son Espases), Fernando Moreno(Hospital Clínico San Carlos), Emilio Esteban(Hospital Universitario Central de Asturias), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Javier Puente(Hospital Clínico San Carlos), Joaquim Bellmunt(Dana-Farber Cancer Institute), Enrique Gallardo(Marqués de Valdecilla University Hospital), Albert Font(Marqués de Valdecilla University Hospital), I. Alemany(Hospital Universitario Fundación Alcorcón), Luis J. Leandro‐García(Spanish National Cancer Research Centre), Susana Hernando(Hospital Universitario Fundación Alcorcón), Manuel M. Morente(Spanish National Cancer Research Centre)
Cited by 74
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k